Bicyclic compounds
AssigneeZeno Royalties & Milestones, LLC
InventorsKevin Duane Bunker, Chuangxing Guo, Mark Charles Grier, Chad Daniel Hopkins, Joseph Robert Pinchman, Deborah Helen Slee, Qinhua Huang, Mehmet Kahraman
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compounds of Formulae (I) and (II), methods of synthesizing compounds of Formulae (I) and (II), and methods of using compounds of Formulae (I) and (II) as an analgesic.
Claims22
A method for reducing pain or fever comprising administering to a subject an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in a subject in need thereof, wherein Formula (I) has the structure:
- wherein:
- R1 is selected from the group consisting of H, D, a substituted or unsubstituted C1-6 alkyl and a substituted or unsubstituted C1-6 haloalkyl;
- R2 is H;
- R3 is selected from the group consisting of D, halo, hydroxy, a substituted or unsubstituted C1-8 alkyl, a substituted or unsubstituted C2-8 alkenyl, a substituted or unsubstituted C2-8 alkynyl, a substituted or unsubstituted C3-20 cycloalkyl, a substituted or unsubstituted C3-20 cycloalkenyl, a substituted or unsubstituted C8-20 cycloalkynyl, a substituted or unsubstituted C6-20 aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heterocyclyl, a substituted or unsubstituted aryl(C1-6 alkyl), a substituted or unsubstituted heteroaryl(C1-6 alkyl), a substituted or unsubstituted heterocyclyl(C1-6 alkyl), a substituted or unsubstituted C1-8 haloalkyl and a substituted or unsubstituted sulfonyl;
- m is 0;
- and
- provided that when R1 is H, then R3 is not t-butyl;
- and provided that a compound of Formula (I), or a pharmaceutically salt thereof, is not
A compound of Formula (I), or a pharmaceutically acceptable salt thereof,
- wherein:
- R1 is selected from the group consisting of H, D, a substituted or unsubstituted C1-6 alkyl and a substituted or unsubstituted C1-6 haloalkyl;
- R2 is H;
- R3 is selected from the group consisting of D, hydroxy, an unsubstituted C1-8 alkyl, a substituted or unsubstituted C2-8 alkenyl, a substituted or unsubstituted C2-8 alkynyl, a substituted or unsubstituted C3-20 cycloalkenyl, a substituted or unsubstituted C8-20 cycloalkynyl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heterocyclyl, a substituted or unsubstituted aryl(C1-6 alkyl), a substituted or unsubstituted heteroaryl(C1-6 alkyl), a substituted or unsubstituted heterocyclyl(C1-6 alkyl), CHF2, CH2F, CF2CH3 and a substituted or unsubstituted sulfonyl;
- and
- m is 0;
- and
- provided that when R1 is H then R3 is not selected from the group consisting of CH3, hydroxy and an unsubstituted t-butyl;
- and provided that a compound of Formula (I), or a pharmaceutically salt thereof, cannot be N,N-diethyl-alpha-methyl-bicyclo[1.1.1]pentane-1-methanamine or
Dependencies are inferred from the claim text.